New Prostate Cancer Drug Developed by Medivation and Astellas Pharma Gets FDA Nod

by Kathy Jones on  September 1, 2012 at 3:55 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

The US Food and Drug Administration has confirmed the approval of a new prostate cancer drug developed by Medivation and Astellas Pharma for men who have failed to respond to hormone therapy and chemotherapy.
 New Prostate Cancer Drug Developed by Medivation and Astellas Pharma Gets FDA Nod
New Prostate Cancer Drug Developed by Medivation and Astellas Pharma Gets FDA Nod

The drug, known as Xtandi, belongs to a new class of drugs known as androgen inhibitors and works by interfering in testosterone's ability to bind prostate cells together. The drug will reportedly cost $7,450 for a 30-day supply with analysts predicting that the sales will reach $1.2 billion by 2017.

The approval has been backed by a number of experts and FDA's director of hematology and oncology products, Richard Pazdur said that it will help extend lives of the patients. "The need for additional treatment options for advanced prostate cancer continues to be important for patients. Xtandi is the latest treatment for this disease to demonstrate its ability to extend a patient's life", he said.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Prostate Cancer Cancer and Homeopathy Trans-Urethral Resection of the Prostate Signature Drug Toxicity Prostate Cancer Facts Cancer Facts Cancer Tattoos A Body Art Prostate Cancer: Treatment Options 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...